KT&G Enters a New Phase On August 29, 2025, KT&G saw a significant change in its ownership structure as the National Pension Service (NPS) became its largest shareholder, replacing the Industrial Bank of Korea. This shift has captured the attention of investors, sparking questions about its potential impact. This article delves into the details of … Read more
Cellomax Science at a Crossroads: Growth vs. Decline – Where’s the Investment Opportunity? Cellomax Science has shown steady growth alongside the expanding health functional food market. However, their recently released H1 2025 report reveals mixed signals of growth and slowdown, leaving investors with a difficult decision. This analysis provides an in-depth look at Cellomax Science’s … Read more
Will Hyundai Green Food Secure Future Growth Engines? On August 28, 2025, Hyundai Green Food held an IR to disclose its current management status and future strategies. The steady growth of its food service, food ingredients, and distribution businesses, along with investments in new businesses like health functional foods and HMR, are positive signals. However, … Read more
Kolmar BNH: Dividend Declared, But Profits Decline? An Investor’s Analysis Kolmar BNH recently announced a dividend, yet the market’s response has been lukewarm. What’s happening with this once steadily growing company? This article delves into the reasons behind Kolmar BNH’s recent performance dip, its future outlook, and provides a comprehensive investment strategy analysis to address … Read more
Kolmar BNH’s Q2 Earnings Surprise: What’s the Real Story? Kolmar BNH recently announced its Q2 2025 earnings, exceeding market expectations with impressive operating profit growth. But what’s the story behind the numbers? We delve into the key growth drivers and future investment strategies, providing actionable insights for investors. 1. Kolmar BNH Q2 Earnings: What Happened? … Read more
Pumtech Korea’s Q2 Earnings Disappoint: Can They Turn Things Around? Pumtech Korea, a specialist in cosmetic containers and health functional foods, held its investor relations (IR) meeting on August 18, 2025. With Q2 results missing market expectations, investor concerns are mounting. We analyze the key takeaways from the IR presentation and discuss potential investment strategies. … Read more
Hyundaibioland’s Turning Point? Earnings Analysis and Investment Strategies Hyundaibioland’s Q2 2025 earnings are out. While exceeding market expectations, the results are overshadowed by declining sales and a net loss. Can Hyundaibioland turn this crisis into an opportunity? This article offers an in-depth analysis of Hyundaibioland’s performance, providing key insights and investment strategies for investors. 1. … Read more
Koryo Pharmaceutical: The Beginning of a Turnaround or the Calm Before the Storm? Koryo Pharmaceutical returned to profitability in the first half of 2025. However, the continuing decline in sales is a concern for investors. While new business expansion and R&D investments offer potential for future growth, potential risks such as the choline alfoscerate lawsuit … Read more
Kobiolab: A Microbiome Leader’s Future Prospects Kobiolab, a key player in the biotech industry, recently announced its H1 2025 earnings. As a leading company in the microbiome market, Kobiolab’s current performance and future outlook are crucial for investors. This report analyzes Kobiolab’s strengths, such as successful tech transfers and clinical trial advancements, while also addressing … Read more
Kolmar Holdings Q2 Earnings: A Turnaround Story? After a disappointing Q1 2025, Kolmar Holdings has reported a rebound in its second-quarter earnings. But is this a temporary reprieve or a sign of a sustained recovery? This blog post provides a comprehensive analysis of Kolmar Holdings’ Q2 2025 earnings, exploring key business trends and investment implications. … Read more